Down's syndrome screening: A controversial test, with more controversy to come!

Journal of Clinical Pathology

Volumn 53, Issue 12, 2000, Pages 893-898

  Reynolds, T M ^a  

^a UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

Nuchal fold; Screening; Trisomy 21

Indexed keywords

CLINICAL PRACTICE; DOWN SYNDROME; GENETIC SCREENING; HUMAN; NATIONAL HEALTH SERVICE; PRACTICE GUIDELINE; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCREENING TEST; STATISTICAL ANALYSIS;

BIOLOGICAL MARKERS; DOWN SYNDROME; FEMALE; FETAL DISEASES; GESTATIONAL AGE; HUMANS; PREGNANCY; PRENATAL DIAGNOSIS; SOFTWARE; ULTRASONOGRAPHY, PRENATAL;

EID: 0033670831     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.53.12.893     Document Type: Review

References (78)

1. Maternal serum screening for Down's syndrome in early pregnancy
2. Serum screening for Down's syndrome: A summary of one year's experience in South Wales
3. Down's syndrome screening in the UK in 1998
4. Dutch doctors call for all pregnant women to be screened for Down's
5. Organisation of screening programmes: The Dutch experience
6. Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency
7. Down's screening news
8. Free β-protein studies need confirmation
9. UKNEQAS for screening for Down's syndrome - Participant survey
10. Screening by test combination: A statistical overview
11. Maternal serum free beta hCG screening: Results of studies including 480 cases of Downs syndrome
12. Maternal serum free beta hCG screening: Results of studies including 480 cases of Downs syndrome - Problems with this approach
13. Improved performance in a prenatal screening programme for Down's syndrome incorporating serum free hCG subunit analyses
14. Prenatal screening for Down's syndrome with use of maternal serum markers
15. Screening for fetal Down syndrome with maternal serum hCG and oestriol: A prospective study
16. Maternal serum screening for fetal Down's syndrome in women less than 35 years of age using alpha-fetoprotein, hCG and unconjugated estriol: A prospective 2 year study
17. Antenatal maternal serum screening for Down's syndrome: Results of a demonstration project
18. Maternal serum screening for alpha-fetoprotein, unconjugated estriol and human chorionic gonadotropin between 11 and 15 weeks of pregnancy to detect fetal chromosome abnormalities
19. Second trimester maternal serum screening using alpha-fetoprotein, human chorionic gonadotropin and unconjugated oestriol: Experience of a regional programme
20. Incremental cost effectiveness of incorporating oestriol evaluation in Down syndrome screening programmes
21. The advantages of using triple-marker screening for chromosomal abnormalities
22. Triple marker (α-fetoprotein, unconjugated estriol, human chorionic gonadotropin) versus α-fetoprotein plus free-β subunit in second trimester maternal serum screening for fetal Down syndrome: A prospective comparison study
23. Maternal serum screening of fetal chromosomal abnormalities by AFP, uE3, hCG and free β-HCG
24. Maternal serum Down syndrome screening: Unconjugated estriol is not useful
25. Sensitivity and specificity of screening for Down syndrome with alpha fetoprotein, hCG unconjugated estriol and maternal age
26. Improved specificity of maternal serum screening for fetal Down syndrome by excluding uE3 level
27. Second trimester unconjugated oestriol levels in maternal serum from chromosomally abnormal pregnancies using an optimized assay
28. Free beta human chorionic gonadotropin in Down's syndrome screening: A multicentre study of its role compared with other biochemical markers
29. The use of unconjugated estriol in Down syndrome screening is unproven
30. Risk of fetal Down's syndrome based on maternal age and varying combinations of maternal serum markers
31. Unconjugated estriol as maternal serum marker for the detection of Down syndrome pregnancies
32. A comparison of unconjugated estriol assay kits shows that expression of results as multiples of the median causes unacceptable variation in calculated Down syndrome risk factors
33. Detection rates and false positive rates for Down's syndrome screening: How precisely can they be estimated and what factors influence their value
34. Maternal serum screening: Free β-protein is a more effective marker than human chorionic gonadotropin
35. Evaluation of an assay of the free beta-subunit of choriogonadotropin and its potential value in screening for Down's syndrome
36. Early detection of Down's syndrome using free beta human choriogonadotropin
37. Prospective study of prenatal screening for Down's syndrome with free beta-human chorionic gonadotropin
38. Free β-HCG subunit versus intact hCG in Down syndrome screening
39. Measurement of choriogonadotropin free β-subunit: An alternative to choriogonadotropin in screening for fetal Down's syndrome?
40. The use of free β-hCG in antenatal screening for Down's syndrome
41. Use of free β-hCG in Down's syndrome screening
42. A comparison of total and free β HCG assays in Down syndrome screening
43. Maternal serum screening for chromosome defects: Human chorionic gonadotropin versus its free-beta subunit
44. Polypeptide nicks cause erroneous results in assays of human chorionic gonadotropin free β-subunit
45. Serum free β-human chorionic gonadotropin concentrations increase in unseparated blood specimens
46. Increased maternal serum free β human chorionic gonadotropin
47. Increased maternal serum free β human chorionic gonadotropin concentrations in Down's pregnancies: An artefactual finding?
48. The stability of blood samples for the measurement of the free β-subunit of chorionic gonadotropin
49. The effect of thermal instability of intact human chorionic gonadotropin (ihCG) on the application of its free β-subunit (free β-hCG) as a serum marker in Down syndrome screening
50. Down's syndrome screening using free β-HCG: Instability can significantly increase the Down's risk estimate
51. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters
52. Prenatal screening for Down's syndrome - A search for the family's values
53. Integrated screening for Down's syndrome
54. Maternal serum pregnancy associated plasma protein A and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy
55. Pregnancy associated plasma protein A (PAPP-A) measurement by highly sensitive and specific enzyme immunoassay, importance of first trimester determinations, and stability studies
56. First trimester serum screening for Down's syndrome
57. Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy
58. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy
59. Prenatal screening for Down's syndrome using inhibin A as a serum marker
60. First trimester aneuploidy screening using nuchal translucency, free beta human chorionic gonadotropin and maternal age
61. First trimester biochemical screening for Down syndrome with the use of PAPP-A, AFP and β-HCG
62. Screening for Down syndrome during first trimester: A prospective study using free β-human chorionic gonadotropin and pregnancy associated plasma protein A
63. First trimester screening for fetal aneuploidy: Biochemistry and nuchal translucency
64. Combining ultrasound and biochemistry in first trimester screening for Down's syndrome
65. Screening of maternal serum for fetal Down's syndrome in the first trimester
66. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy
67. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation
68. Antenatal screening for Downs syndrome: Where are we and where next?
69. Antenatal screening for Down's syndrome
70. Antenatal screening for Down's syndrome
71. Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: Population based cohort study
72. Down's syndrome, cardiac anomalies and nuchal translucency
73. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A
74. Response to Wald and Hackwell
75. Response to Wald and Hackwell
76. Serum screening for Down's syndrome: National policy would ensure consistency